Mediancer.com The DMV Federal Report

Federal Courts.
Government Accountability.
The DMV and Beyond.

Opinion analysis

A generic drug’s narrow label did not make out a patent-inducement claim

A unanimous Supreme Court found the complaint lacked facts plausibly alleging active encouragement of a patented use.

The U.S. Supreme Court Building at dusk.
Context photograph. Noclip · Public domain. See Image Credits.

A generic medicine can be approved for a use no longer protected by patents while leaving a patented use off its labeling. When Amarin sued Hikma over a generic version of Vascepa, the Supreme Court had to decide whether that narrow label and Hikma’s other statements plausibly showed that it actively encouraged use of the drug for the still-patented purpose.

Vascepa had federal approvals for separate uses. Hikma obtained generic approval for the severe hypertriglyceridemia indication and excluded the indication tied to cardiovascular risk reduction. Amarin alleged that the label, patient materials, website and press releases together encouraged infringement of its method-of-use patents. A Delaware federal court dismissed the complaint, and the Federal Circuit allowed it to proceed.

Justice Ketanji Brown Jackson’s unanimous decision looked for facts supporting active inducement under 35 U.S.C. § 271(b). The question was whether Hikma affirmatively encouraged an infringement, rather than whether a doctor could read a statement and later prescribe the drug for an infringing use. Some label language was explained by statutory labeling requirements, and describing the drug as a generic equivalent was consistent with ordinary industry practice. Omissions and vague statements were insufficient.

The Court reversed the Federal Circuit and remanded. It decided the sufficiency of the pleaded facts without adjudicating an actual prescription, determining infringement in a particular patient’s case, or creating a categorical defense for generics using a so-called skinny label.

The distinction matters for product announcements. A statement can accurately identify a generic’s relationship to its branded version without directing a third party toward every patented use associated with the original. Active inducement turns on what actions the defendant is plausibly alleged to have taken to bring infringement about.

Source Documents

  1. Supreme Court opinion and separate writings
  2. Supreme Court docket
Share by email Corrections policy

Related reporting